Find your next paid study

Tango Therapeutics, Inc.NCT06922591

~$150 – $4,200

Actual pay is set by the research site.

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Immuneering CorporationNCT07562152

Actual pay is set by the research site.

Phase 1

A Phase 1 Study With Expansion of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PANACEA)

The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for…

Pancreas CancerPancreatic Cancer MetastaticPancreatic Cancer (Unresectable)

Marker Therapeutics, Inc.NCT06549751

~$150 – $4,200

Actual pay is set by the research site.

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compare…

Revolution Medicines, Inc.NCT07805954

Actual pay is set by the research site.

Phase 1

Phase Ib Randomized Study of Gemcitabine (G) With Nab-paclitaxel With or Without Pitavastatin (P) in the Maintenance Treatment of Unresectable Pancreatic Adenocarcinoma (uPDAC)

This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjec…

Pancreatic CancerPancreatic Cancer Metastatic

University of California, IrvineNCT07549958

~$150 – $3,000

Actual pay is set by the research site.

Phase 2

A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)

This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibo…

Pancreatic Cancer Metastatic

Massachusetts General HospitalNCT07765836

~$75 – $2,000

Actual pay is set by the research site.

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with che…

Revolution Medicines, Inc.NCT07491445

Actual pay is set by the research site.

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo…

Revolution Medicines, Inc.

Actual pay is set by the research site.

Phase 2

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-10…

Pancreatic Cancer MetastaticPancreatic Ductal AdenocarcinomaPancreatic Cancer Stage IV

Panbela Therapeutics, Inc.NCT05254171

~$75 – $2,800

Actual pay is set by the research site.

Phase 2

A Randomized Phase II Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Advanced Pancreatic and Colorectal Cancer (CanPan-C)

Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (cal…

Pancreatic Cancer Non-resectablePancreatic Cancer MetastaticColorectal Cancer Metastatic

HealthPartners InstituteNCT06605430

~$75 – $3,000

Actual pay is set by the research site.

Phase 1

Phase 2A Pilot Trial of Metformin, Digoxin, Simvastatin (C3) in Combination With Gemcitabine in Subjects With Recurrent / Refractory Metastatic Advanced Pancreatic Cancer

The goals of this trial are: 1) To evaluate the safety and tolerability of C3 administration with Gemcitabine; and 2) To assess the disease response following …

Pancreatic Cancer Metastatic